Salamanca

• This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin … Recruiting
  2023-505347-38-00 9 2022-06-13 B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma
• EARLY treatment with Candesartan vs Placebo in asymptomatic GENEtic carriers of Dilated Cardiomyopathy (EARLY-GENE trial) Recruiting
  2023-507029-40-00 5 2022-05-09 Genetic carriers of dilated cardiomyopathy causing variants
• A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer … Recruiting
  2024-512089-32-00 3 2022-03-28 Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
• Study of BGB-11417 in Patients with Myeloid Malignancies Recruiting
  2023-508881-14-00 9 2022-03-21 Myeloid malignancies (acute myeloid leukemia (AML), myelodysplastic sy
• Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten (CK-3773274) in Adults With Hypertrophic Cardiomyo … Recruiting
  2023-508963-58-00 4 2022-01-31 Symptomatic hypertrophic cardiomyopathy (HCM)
• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituxim … Recruiting
  2024-510690-16-00 5 2022-01-31 Relapsed/refractory follicular lymphoma
• DZR123 (CPI-0209) in Patients with Advanced Solid Tumors and Lymphomas Recruiting
  2023-508002-20-00 7 2021-10-21 advanced, solid, relapsed tumors / advanced tumors: human lymphomas /
• An early phase clinical trial to investigate EO2463, a novel cancer vaccine therapy, in patients with indolent Non-Hodgkin's Lymphoma. Recruiting
  2023-509254-58-00 7 2021-05-31 Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma; Marginal Zone Ly
• Clinical trial to asses the efficacy and safety of a vaccine for grasses and cupressaceae allergy Recruiting
  2024-514524-16-00 5 2021-05-11 Aetiological treatment of moderate-severe intermitent or persistent al
• A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies Recruiting
  2023-504931-42-00 4 2021-04-06 Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters tran
• Radiation-Free Therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negativ … Recruiting
  2024-515063-66-00 4 2021-03-30 Early stage classical Hodgkin Lymphoma (cHL) without bulky lesions and
• Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma Recruiting
  2024-511454-45-00 7 2020-11-09 Relapsed or Refractory Multiple Myeloma
• Long-term efficacy, safety and tolerability of LNP023 in C3G or IC-MPGN Recruiting
  2023-509343-27-00 11 2019-10-28 C3 Glomerulopathy or idiopathic immune-complex membranoproliferative g
• An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) Recruiting
  2024-515690-10-00 9 2019-05-10 Follicular B-cell non-Hodgkin's lymphoma
• Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. Recruiting
  2023-504201-36-00 10 2018-12-21 Defined by parent protocol. The study will enroll all adult and paedia
• LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting
  2022-502706-33-00 6 2018-01-10 Patients with invasive breast cancer in early stages
• CAR T-cell therapy long term follow-up Recruiting
  2023-508128-37-00 5 2017-07-19 All patients who have been treated with Novartis or Penn CAR T-cell th
• A Phase 1/2a Study of UCART22 in B-cell Acute Lymphoblastic Leukemia (BALLI-01) Ended recruitment
  2022-502305-15-00 7 2025-11-26 Relapsed or refractory B-cell Acute Lymphoblastic Leukemia
• Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris … Ended recruitment
  2023-508827-10-00 4 2025-10-13 Patients with primary operable stage II, grade 2 or 3, Ki67 #20%, HR+/
• A Study to Test Inavolisib Treatments in Patients with Early-Stage, PIK3CA-Mutated Breast Cancer Ended recruitment
  2024-518811-20-00 4 2025-09-30 Early-Stage, PIK3CA-Mutated Breast Cancer (BC)
• A study to test whether vicadrostat in combination with empagliflozin helps people with chronic kidney disease Ended recruitment
  2024-518457-42-00 4 2025-08-28 chronic kidney disease
• A Phase 2, open-label study to evaluate the efficacy and safety of anitocabtagene autoleucel in participants with newly diagnosed multiple m … Ended recruitment
  2024-517020-18-00 4 2025-06-30 Newly diagnosed multiple myeloma according to IMWG criteria
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended recruitment
  2024-512925-95-00 5 2025-05-16 Advanced/Metastatic Breast Cancer
• A clinical study to evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Comb … Ended recruitment
  2023-505792-71-00 4 2025-03-13 Multiple Myeloma

Showing 193–216 of 470 trials